EUCTR2005-001856-19-CZ进行中（未招募）不适用
A Phase III Randomized, Multicenter, Multinational, Double-Masked,Placebo-Controlled Study of Photrex™ (Rostaporfin) PhotodynamicTherapy in the Treatment of Classic and Occult Subfoveal ChoroidalNeovascularization Associated with Age-Related Macular Degeneration
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females, 50 years of age or older
- •2. Able to understand and give written informed consent prior to performing any study related procedures.
- •3. CNV consistent with AMD in study eye.
- •4. At screening the active CNV lesions in the study eye:
- •Must have at least one subfoveal CNV membrane secondary to AMD that can be clearly demonstrated by FA.
- •Area of lesion components must not exceed 3 DA. Here, lesion components are defined as CNV plus adjacent blocked fluorescence and blood that may obscure underlying CNV. Furthermore, subretinal fibrous tissue is considered a lesion component. Determination of lesion size and composition will be
- •made by the Fundus Photograph Reading Center (FPRC), Madison, WI.
- •Must not be developing an early disciform scar that is greater than 25% of the
- •area of the lesion as judged from clinical examination and/or color
- •photographs (as determined by the FPRC, Madison, WI).
- •In each subject only one lesion in one study eye may be treated with rostaporfin-
- •PDT. Selection of the study eye is at the discretion of the investigator.
- •5. At screening the purely occult CNV lesions in the study eye must exhibit evidence of SSRD or PED, with the size of SSRD or PED being at least 2 DA (as determined by
- •the FPRC, Madison, WI).
- •6. Must have a best-corrected Screening visual acuity score of 34 – 70 ETDRS (Early TreatmentDiabetic Retinopathy Study) letters (Snellen-equivalent approximately 20/200 to 20/40).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous laser treatment for subfoveal macular disease in the study eye.
- •2. Anterior segment abnormalities including those of the cornea, anterior chamber, iris, or lens that would preclude adequate examination of the ocular fundus or obtaining good quality images. The pupil of the study eye cannot be dilated to = 4 mm.
- •3. Ocular surgery (excluding yttrium aluminum garnet [YAG] capsulotomy) in the study
- •eye within the past three months.
- •4. Glaucoma of any type, in the study eye, if the cup/disc ratio is = 0.8 or if field loss is advanced (= 10 decibel decrease in the automatic perimeter in the 30-degree central visual field).
- •5. Ocular disease of any type in the study eye that could independently affect VA of the study eye, such as diabetic retinopathy (>10 microaneurysms or small retinal
- •hemorrhages), high axial myopia (>-8.00 diopters), pattern dystrophy, epiretinal
- •membranes, nevus associated with neovascular membrane, macular hole with or
- •without neovascular membranes, nystagmus, branch vein occlusion or RPE
- •abnormalities other than AMD.
- •6. Dense submacular hemorrhage = 50% of study lesion area (a pseudopod of blood
- •extending from the lesion that is so narrow as to be unlikely to obscure underlying
- •CNV is excluded when determining lesion area).
- •7. CNV from other disease, i.e., high myopia (axial length >8 diopters), angioid streaks, pseudoxanthoma elasticum, presumed ocular histoplasmosis or idiopathic CNV.
- •8. Pigmentation of the macular or paramacular region from the prior use of any maculaaffecting drugs such as hydroxychloroquine, chloroquine, thioridazine, other
- •phenothiazine derivatives, or any use of these drugs within the last 12 months.
- •9. Use of an investigational drug or other investigational therapy within 30 days prior to study drug dosing.
- •10. Intravitreal injections administered in the study eye within 6 months prior to study entry.
- •11. Use of any systemic or topical PDT agents.
- •12. Use of Thalidomide for treatment of AMD or other diseases.
- •13. Known allergic or hypersensitivity reactions to light, fluorescein, egg proteins, or eggyolk.
- •14. History of porphyria, systemic lupus erythematosus, or xeroderma pigmentosum.
- •15. Known disorder of lipoprotein metabolism or clearance (cholesterol> 400 mg/dl,
- •and/or triglycerides > 500 mg/dl).
- •16. Gamma glutamyl transferase (GGT) at study entry = 2.5 times upper limit of normal.
- •17. Compromised hepatic function within 14 days of therapy (i.e., bilirubin >1.5 times
- •the upper limit of normal, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) or alkaline phosphatase > 2.5 times the upper limit of normal levels).
- •18. Compromised cardiovascular function (i.e., myocardial infarction (MI) within the
- •past 6 months, clinically significant arrhythmia, or clinically significant conduction
- •abnormalities).
- •19. Presence of significant coronary artery disease that requires ongoing coumarin
- •anticoagulants therapy, which include warfarin and dicumarol. (Aspirin antithrombotic therapy will not exclude subjects.)
- •20. Significant pulmonary insufficiency reported within the last 12 weeks.
- •21. The presence of any disease that would make survival for the study period unlikely or that severely limits the study subjects’s daily activity, or is likely to limit activity within 2 years, to the extent that the study subjects would be unable to return for regular follow-up visits.
- •22. Pregnancy or a positive urine pregnancy test result within 7 days of treatment, or
研究者
相似试验
进行中（未招募）
1 期
Belimumab in Remission of VasculitisEUCTR2011-004569-33-GBHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)106
进行中（未招募）
1 期
Belimumab in Remission of VasculitisWegener’s granulomatosis (WG)Microscopic polyangiitis (MPA)VasculitisMedDRA version: 16.1Level: LLTClassification code 10047888Term: Wegener's granulomatosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 16.1Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-004569-33-HUHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)400
进行中（未招募）
1 期
Belimumab in Remission of VasculitisWegener's granulomatosis (WG)Microscopic polyangiitis (MPA)VasculitisMedDRA version: 14.1Level: PTClassification code 10047888Term: Wegener's granulomatosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 14.1Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-004569-33-ESHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)400
进行中（未招募）
1 期
Belimumab in Remission of VasculitisWegener’s granulomatosis (WG)Microscopic polyangiitis (MPA)VasculitisMedDRA version: 16.1Level: LLTClassification code 10047888Term: Wegener's granulomatosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 16.1Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-004569-33-SEHuman Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)400
进行中（未招募）
不适用
Belimumab in Remission of VasculitisWegener's granulomatosis (WG) Microscopic polyangiitis (MPA) VasculitisMedDRA version: 15.1Level: LLTClassification code 10047888Term: Wegener's granulomatosisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 15.1Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-004569-33-ITHUMAN GENOME SCIENCES INC400